| abstract |
The present invention addresses the problem of providing a new drug that, with respect to autoimmune diseases or blood cancer, is for preventing, suppressing the advance of symptoms, suppressing recurrence, or treating such diseases. The inventors of the present invention conducted extensive studies, and came to focus on a PD-1/CD4 dual-specific protein as a substance that can solve the foregoing problem, leading to completion of the present invention. The PD-1/CD4 dual-specific protein according to the present invention is configured to reduce the induction of generation or release of cytokine that occurs when the protein is administered. As a result, it can be expected that infusion reaction or cytokine release syndrome that could occur upon administration of the protein is suppressed. |